Teneobio
Biotechnology, 7999 Gtwy BLVD, Newark, California, 94560, United States, 11-50 Employees
Phone Number: 65********
Who is TENEOBIO
TeneoBio, Inc. is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious...
Read More
-
Headquarters: 7999 Gtwy BLVD, Newark, California, 94560, United States
-
Date Founded: 2009
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Teneobio Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Teneobio
Answer: Teneobio's headquarters are located at 7999 Gtwy BLVD, Newark, California, 94560, United States
Answer: Teneobio's phone number is 65********
Answer: Teneobio's official website is https://teneobio.com
Answer: Teneobio's revenue is $10 Million to $25 Million
Answer: Teneobio's SIC: 8731
Answer: Teneobio's NAICS: 541714
Answer: Teneobio has 11-50 employees
Answer: Teneobio is in Biotechnology
Answer: Teneobio contact info: Phone number: 65******** Website: https://teneobio.com
Answer: TeneoBio, Inc. is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases. TeneoBio has several products in pre-clinical and clinical development for the treatment of multiple myeloma, prostate cancer, and immune disorders. TeneoBio’s antibody discovery engine is based on UniRat™, a proprietary heavy chain only, human immunoglobulin transgenic rat. We apply a novel sequence-based discovery approach using NGS, bioinformatics and high-throughput recombinant protein expression. This approach identifies a large set of diverse UniAb leads with broad epitope coverage of target antigens. The high affinity and robust function of UniAbs combine antibody specificity with excellent developability. The UniAbs’ fully human VH domains, UniDabs™, are versatile building blocks that can be linked to Fc’s or serum albumin for the development of novel therapeutics with multi-specificity, increased potency and extended half-life. To enable the development of platforms for T cell redirection, TeneoBio has produced many high-affinity UniAbs specific for human CD3 and various tumor antigens. Such bispecific therapeutic antibodies against multiple myeloma cells are currently in preclinical development. Blockade of immune checkpoints has been shown to direct T cells against tumors for therapeutic benefit. TeneoBio has produced several such high-affinity UniDab™ blockers against various checkpoint inhibitors, laying the foundation for multi-specific anti-cancer therapeutics in the immune-oncology space.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month